Aptevo Therapeutics Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires listed companies to maintain at least $2.5 million in stockholders’ equity, a critical benchmark for continued listing on the exchange.
The company received a positive signal from Nasdaq, confirming its adherence to the equity requirement. This achievement resolves a significant compliance concern, which is important for maintaining investor confidence and market access.
Regaining Nasdaq compliance removes a potential delisting risk, providing greater stability for the company's shares. This development ensures Aptevo can continue to trade on the Nasdaq Capital Market, which is vital for its visibility and ability to raise capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.